Loading...
Percutaneous coronary intervention (PCI) in patients at high risk for bleeding is challenging because conventional, polymer-based, drug-eluting stents (DES) require prolonged dual antiplatelet therapy (DAPT). Traditionally, these patients have been treated with bare-metal stents requiring only 1 month of DAPT, but recently a non–polymer-based drug-coated stent (DCS) was shown to be both safer and more effective than bare-metal stents for patients treated with only 1 month of DAPT. To investigate outcomes with a widely available, current-generation DES, researchers in an industry-sponsored trial (NCT03344653) randomized 1996 patients at high bleeding risk to either durable polymer-based zotarolimus-eluting stents (DES; Resolute Onyx) or poly…